Parsec Financial Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Parsec Financial Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$7.12M	Buy	22,584 +126	+0.6%	+$37.8K	0.3%	73
2022 Q4	$6.49M	Buy	22,458 +2,136	+11%	+$651K	0.29%	77
2022 Q3	$5.88M	Buy	20,322 +7,531	+59%	+$2.17M	0.29%	74
2022 Q2	$3.6M	Buy	12,791 +348	+3%	+$93.1K	0.17%	94
2022 Q1	$3.25M	Buy	12,443 +6,226	+100%	+$1.48M	0.14%	110
2021 Q4	$1.36M	Sell	6,217 -235	-4%	-$45.7K	0.06%	151
2021 Q3	$1.23M	Buy	6,452 +2,304	+56%	+$450K	0.05%	149
2021 Q2	$836K	Buy	4,148 +1,921	+86%	+$402K	0.04%	160
2021 Q1	$479K	Buy	+2,227	New	+$489K	0.02%	191

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parsec Financial Management's VRTX Position: Q1 2023 in Review

Parsec Financial Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.56% in Q1 2023, buying an estimated $37.8K and bringing the position to 22,584 shares worth $7.12M. The position accounts for 0.3% of the portfolio, ranked #73.

Parsec Financial Management first reported a position in VRTX in Q1 2021 and has held it in 9 quarters since. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Parsec Financial Management held 22,584 shares of Vertex Pharmaceuticals worth $7.12M as of Q1 2023.
Parsec Financial Management bought 126 Vertex Pharmaceuticals shares in Q1 2023, an estimated $37.8K.
Vertex Pharmaceuticals made up 0.3% of Parsec Financial Management's portfolio in Q1 2023, its #73 holding.
Parsec Financial Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Parsec Financial Management's 13F filing for Q1 2023, filed 6 Apr 2023.